1 overall survival, respectively, with 5 years
median follow-up time.
2 On follow-up (
median follow-up time 11.9 months, range 8-24), there wa
3 With a
median follow-up time 12 years in S0014, 5- and 10-year
4 In 32 patients (
median follow-up time,
3.2 years) with rCR who did not u
5 following 4,123 healthy men every 6 months (
median follow-up time,
4.1 years).
6 positive viremic women with HIV coinfection (
median follow-up time,
5.2 years).
7 with follow-up ranging from 1 to 11 visits (
median follow-up time,
5.5 years; range, 1.4-32.7 years,
8 hnicity (97% vs. 99% European; P = 0.3), and
median follow-up time (
6.5 years vs. 3 years; P = 0.3).
9 ata were available for 290 Native Americans (
median follow-up time:
6.6 years).
10 NODM was reported in 4.6% (
median follow-up time:
693 days).
11 3 recipients without pretransplant diabetes (
median follow-up time,
713 days).
12 atus was followed through December 30, 2003 (
median follow-up time,
97 months).
13 The
median follow-up time after 3D-CRT was 42 months.
14 the basis of 271 occurrences of HF during a
median follow-up time after cohort entry of 17.3 years (
15 The
median follow-up time after cure was 11 months, during w
16 Median follow-up time after HCT was 36.6 months.
17 Median follow-up time after implant placement was 6 year
18 The
median follow-up time after random allocation was 10.3 y
19 The
median follow-up time after randomization was 54 months
20 Median follow-up time after recurrence was 11.5 months.
21 The
median follow-up time after the first RTX course was 36.
22 With a
median follow-up time among survivors of 7.6 years (rang
23 With a
median follow-up time among survivors of 7.6 years (rang
24 Median follow-up time among the 46 patients who remain a
25 The
median follow-up time and number of visits were 1.7 year
26 The
median follow-up time for 228 surviving patients was 6.6
27 Median follow-up time for 92 (52%) surviving patients wa
28 The
median follow-up time for all 1,236 eligible and assessa
29 The
median follow-up time for all 114 subjects was 26.70 mon
30 The
median follow-up time for all patients was 69 months; 79
31 At a
median follow-up time for all randomised patients of 12.
32 us as potentially associated with prognosis (
median follow-up time for genotypes: CC = 4 years, CT =
33 The
median follow-up time for hemoglobin measurement for mot
34 ployees (n = 2,476) was 8,469 years, and the
median follow-up time for participants was 4.0 years.
35 Median follow-up time for patients alive at time of anal
36 Median follow-up time for survival analysis was 20.0 mon
37 With a
median follow-up time for surviving patients of 69 month
38 With a
median follow-up time for survivors of 37 months, diseas
39 Median follow-up time for survivors was 27 months.
40 The
median follow-up time for the 70 patients enrolled was 3
41 The
median follow-up time for the cohort was 5.17 years afte
42 Median follow-up time for the cohort was 58 months.
43 With a
median follow-up time for the study group of 20 months,
44 The
median follow-up time for this cohort was 5.1 years (199
45 Median follow-up time from baseline (defined as the time
46 The
median follow-up time from complete response to last con
47 The
median follow-up time from CR date in the 36 patients al
48 The
median follow-up time from diagnosis for all alive patie
49 Among the 819 survivors, the
median follow-up time from the first biopsy is 6.4 years
50 Median follow-up time from transplantation to end of fol
51 The
median follow-up time in MADIT-II, SCD-HeFT, and the ICD
52 The
median follow-up time in survivors was 4.4 years.
53 The
median follow-up time in this study is 44 months (range,
54 months, and median OS has not been reached;
median follow-up time is 10.7 months.
55 Median follow-up time (
n = 111) was 1.8 years (range, 1
56 SVTs despite 3 ablation procedures during a
median follow-up time of >200 days.
57 At a
median follow-up time of 10 months, median survival time
58 During a
median follow-up time of 10.1 years (interquartile range
59 a persistent response to vemurafenib, with a
median follow-up time of 10.5 months (range, 6 to 16 mon
60 Over a
median follow-up time of 10.7 years (56,403 total person
61 During a
median follow-up time of 10.7 years, there were 1,105 co
62 During a
median follow-up time of 10.9 years (interquartile range
63 After a
median follow-up time of 11 months, the median overall s
64 With a
median follow-up time of 12 months and 382 deaths, there
65 After a
median follow-up time of 12.8 y, 23,828 deaths were iden
66 allograft function and proteinuria during a
median follow-up time of 1386 days (range, 332-6254).
67 With a
median follow-up time of 14 months, median progression-f
68 icipants, 1,496 deaths were recorded after a
median follow-up time of 14 years (1998-2012).
69 ages ranged from 3 months to 66 years, with
median follow-up time of 15 months.
70 After a
median follow-up time of 15 y, prostate cancer was diagn
71 At a
median follow-up time of 16 months (26 months in patient
72 In the MDCS, over a
median follow-up time of 16.1 years, aortic stenosis dev
73 s is 90%, and all patients are alive after a
median follow-up time of 17 months.
74 0 eyes from 13 patients were included with a
median follow-up time of 17 months.
75 PFS) and disease-specific mortality during a
median follow-up time of 18 months (range, 4-35 months).
76 During a
median follow-up time of 18 months, 102 (24%) were hospi
77 With a
median follow-up time of 18 months, 55 patients (76%) ha
78 n, who achieved complete remission and had a
median follow-up time of 18.7 years (range, 2.4-41.3 yea
79 had progressed in 17 patients (5.1%) after a
median follow-up time of 19 months.
80 induced sustained clinical remission with a
median follow-up time of 2 years.
81 t laparoscopic AGB or RYGB procedures with a
median follow-up time of 2.3 years (maximum, 6 years).
82 Over a
median follow-up time of 2.76 years (interquartile range
83 After a
median follow-up time of 21.9 months (IQR 12.1-31.0) in
84 atients were enrolled onto the study, with a
median follow-up time of 215 days.
85 Seventy-two patients were included with a
median follow-up time of 22 months.
86 -seven eligible patients were accrued with a
median follow-up time of 22.2 months.
87 With a
median follow-up time of 23 months, the median response
88 values did not differ significantly during a
median follow-up time of 24 months (median intra-patient
89 s is 88%, and all patients are alive after a
median follow-up time of 24 months.
90 After a
median follow-up time of 24.3 years (mean = 25.6 years),
91 With a
median follow-up time of 25 months, the estimated 3-year
92 With a
median follow-up time of 26 months and 54 progression ev
93 With a
median follow-up time of 26 months, the 2-year survival
94 After a
median follow-up time of 26 months, VT recurred in 164 (
95 s underwent a total of 19 procedures, with a
median follow-up time of 26.4 months.
96 st follow-up, 99 patients were alive, with a
median follow-up time of 27 months (range, 2 to 151 mont
97 Now, with a
median follow-up time of 27 months, median survival time
98 After a
median follow-up time of 27.3 weeks, patients with a pro
99 Over a
median follow-up time of 28 (11-48) months, 18 patients
100 erall survival is not yet assessable, with a
median follow-up time of 28 months.
101 At a
median follow-up time of 3 years (interquartile range, 2
102 Over a
median follow-up time of 3.01 (interquartile range=1.56-
103 uring subsequent annual surveillance, with a
median follow-up time of 3.1 years (interquartile range,
104 ith T2DM, 20.1% and 7.2% developed DR over a
median follow-up time of 3.2 and 3.1 years, respectively
105 ratio, 1.16; 95% CI, 0.97 to 1.38) during a
median follow-up time of 3.3 years.
106 Results With a
median follow-up time of 3.4 years, the estimated cumula
107 e selected a total of 7,465 patients, with a
median follow-up time of 3.5 years for patients still al
108 nts and 46% for CHOP patients (P = .04) at a
median follow-up time of 3.5 years.
109 At a
median follow-up time of 31 months, median PFS was 42 mo
110 With a
median follow-up time of 32 months, the median overall s
111 At a
median follow-up time of 33 months, locoregional or syst
112 mmol/l, 95%CI:0.26-0.74, p = 0.002) after a
median follow-up time of 33(21-36) months.
113 During a
median follow-up time of 35 months (interquartile range,
114 from November 2006 through July 2012, with a
median follow-up time of 35 months in an ambulatory care
115 With a
median follow-up time of 35 months, two (4.8%) of 41 pat
116 Results After a
median follow-up time of 35.7 months, 190 patients had d
117 e partial tumor response are ongoing after a
median follow-up time of 36 months (range, 22 to 43 mont
118 During a
median follow-up time of 37 months, 4-year estimates of
119 ocardiographic follow-up were completed at a
median follow-up time of 37 months.
120 With a
median follow-up time of 38.7 months, the median surviva
121 With a
median follow-up time of 39.6 months, median overall sur
122 2 controls from 7 European countries after a
median follow-up time of 4.1 years.
123 , and worse overall survival (P = .006) at a
median follow-up time of 4.1 years.
124 with a diagnosis of prostate cancer after a
median follow-up time of 4.2 y and 1061 matched controls
125 TTs) and 99.6% in the low-risk group, with a
median follow-up time of 4.2 years.
126 us, and cause of death were documented for a
median follow-up time of 4.8 y.
127 During a
median follow-up time of 4.8 years, there were 339 (60%)
128 us, and cause of death were documented for a
median follow-up time of 4.9 y.
129 With a
median follow-up time of 40 months, the 3-year FFS and o
130 nts (51%) are alive and free of disease at a
median follow-up time of 40 months.
131 imary carotid body paraganglioma resections (
median follow-up time of 42 months, range: 1-293).
132 ompleted 24 weeks of double-blind treatment (
median follow-up time of 42 weeks), patients in the emtr
133 At a
median follow-up time of 43 months, 4-year progression-f
134 With a
median follow-up time of 43 months, the nonrelapse morta
135 st follow-up, 560 patients were alive with a
median follow-up time of 45 months (range, 1-264 months)
136 With a
median follow-up time of 45 months, the major cytogeneti
137 nts were obtained at recruitment and after a
median follow-up time of 5 y.
138 During a
median follow-up time of 5 years, 124 CVD events occurre
139 mission and no evidence of recurrence over a
median follow-up time of 5 years.
140 During a
median follow-up time of 5.1 years (IQR 2.6-7.5), we rec
141 After a
median follow-up time of 5.1 years, the estimated 5-year
142 l of 7542 recipients were followed up over a
median follow-up time of 5.3 years (interquartile range
143 0.64 years of age had available data after a
median follow-up time of 5.33 years in the GnRHa group a
144 With a
median follow-up time of 5.5 years, the median PFS was 3
145 Median follow-up time of 51.1 months.
146 After a
median follow-up time of 53 months, the actuarial median
147 or PCO was obtained from 270 patients with a
median follow-up time of 57 months (range 50-64 months).
148 During the
median follow-up time of 57 months, 350 children develop
149 le range, 35 to 58 years) at diagnosis and a
median follow-up time of 58 months (interquartile range,
150 With a
median follow-up time of 58 months, PFS at 5 years was 6
151 matory drug (NSAID) users (n = 315).During a
median follow-up time of 59 mo, 200 participants (43.8%)
152 With a
median follow-up time of 59 months for 2,181 patients st
153 During a
median follow-up time of 59 months, 214 RFS events occur
154 nt and persistent disease (P = 0.009) with a
median follow-up time of 6.0 years.
155 With a
median follow-up time of 6.3 months, the quality of life
156 At a
median follow-up time of 6.3 years, there were no statis
157 With a
median follow-up time of 60 months (range, 19-94), the e
158 The study was closed after a
median follow-up time of 60 months, with a relapse rate
159 lete response in 92% of patients, and at the
median follow-up time of 62 months, the progression-free
160 of NODM was 26.4% in liver recipients with a
median follow-up time of 685 days.
161 With a
median follow-up time of 69 months (range, 6-112 months;
162 patients are continuously disease free at a
median follow-up time of 69 months, resulting in a 63% d
163 Results With a
median follow-up time of 7.4 years, 25 (11.6%) of 216 pa
164 As of September 2005, with a
median follow-up time of 7.9 years, of the 482 patients
165 were more likely to remain carriers after a
median follow-up time of 70 days than women not using su
166 At a
median follow-up time of 70 months, ILC patients tended
167 herapy, and no metastases were recorded in a
median follow-up time of 73.2 months (mean, 71.5; range,
168 With a
median follow-up time of 73.9 months (interquartile rang
169 With a
median follow-up time of 76 months, no differences were
170 At a
median follow-up time of 79.5 months for all surviving p
171 At a
median follow-up time of 8 years, 465 patients had died,
172 After a
median follow-up time of 8.3 years (range, 0-26 years),
173 After a
median follow-up time of 8.3 years, the median survival
174 th HF with preserved ejection fraction and a
median follow-up time of 8.6 years.
175 After a
median follow-up time of 8.7 y, prostate cancer was diag
176 the patients are alive without disease at a
median follow-up time of 8.9 years from diagnosis.
177 After a
median follow-up time of 84 months, event-free and overa
178 Over a
median follow-up time of 9.1 years (interquartile range,
179 ity was observed in 40% of patients during a
median follow-up time of 9.7 years.
180 With a
median follow-up time of 964 days (range, 569 to 1,162 d
181 still experienced wheat sensitivity after a
median follow-up time of 99 months.
182 At a
median follow-up time of about 5 years, 61 participants
183 Over a
median follow-up time of approximately 4 years, after ad
184 The
median follow-up time of living patients was 124.5 month
185 Median follow-up time of the 15 patients still alive at
186 ponse was not reached in either cohort, with
median follow-up times of 12.8 months (IQR 9.3-15.5) in
187 dence, 1.3%) in the primary OAC group during
median follow-up times of 42.6 months (range, 6.2-97.1 m
188 With
median follow-up times of 86 months in the DA-EPOCH-R gr
189 Median follow-up time ranged from 22 to 51 months in the
190 age was 31.2 years (range, 0.5-55.6 years);
median follow-up time since randomization was 4.2 years.
191 With 60-month
median follow-up time,
the overall RR for 121 assessable
192 The
median follow-up time to assess platelet responses was 1
193 The
median follow-up time to death or last survey since ALL
194 Median follow-up time to first SMN diagnosis was 26.3 ye
195 Median follow up time was 24 months.
196 For diabetes assessment, the
median follow-up time was 10 years (interquartile range
197 Median follow-up time was 10.8 years (range, 0 to 16.9 y
198 Median follow-up time was 10.9 years.
199 Median follow-up time was 11.1 years.
200 The
median follow-up time was 12 months (5 days-7 years), bu
201 The
median follow-up time was 12 years.
202 Median follow-up time was 12.3 years.
203 Median follow-up time was 12.6 (to a maximum of 28.2) ye
204 The
median follow-up time was 136 months.
205 The
median follow-up time was 14.5 months.
206 Median follow-up time was 15.1 years.
207 The
median follow-up time was 15.5 y.
208 The
median follow-up time was 15.8 years.
209 Median follow-up time was 155 days (IQR 77-357) in the p
210 Median follow-up time was 16.8 months (range, 3.4-84.8 m
211 The
median follow-up time was 160 days.
212 For diabetes complications, the
median follow-up time was 17.6 years (IQR, 14.2-19.8) an
213 Median follow-up time was 2.0 years (IQR 1.9-3.0).
214 Median follow-up time was 2.4 (0.9-4.0) years.
215 The
median follow-up time was 2.5 years.
216 Median follow-up time was 2.6 (0.8-4.5) years.
217 The
median follow-up time was 2.7 years.
218 Median follow-up time was 2.8 years (range, 1 day to 16.
219 Median follow-up time was 20.0 months (IQR 15.0-25.6) in
220 The
median follow-up time was 23 months (interquartile range
221 Median follow-up time was 23.1 months.
222 Median follow-up time was 24 (range, 3-112) weeks.
223 Median follow-up time was 24 months (IQR 20-25) in the n
224 ce interval (CI): 19.8-22.5 months], whereas
median follow-up time was 25.1 months (95% CI: 23.5-26.5
225 Median follow-up time was 26.3 months (range, 2.0-47.2 m
226 For 518 patients, the
median follow-up time was 29.3 months (range, 1 to 149 m
227 Median follow-up time was 29.7 months (95% confidence in
228 The
median follow-up time was 3.0 years.
229 The
median follow-up time was 3.1 years.
230 The
median follow-up time was 3.3 years.
231 The
median follow-up time was 3.5 years for the ATG group an
232 Median follow-up time was 3.8 years.
233 The
median follow-up time was 3.94 years.
234 The
median follow-up time was 30 months (range, 1-109).
235 Median follow-up time was 32 months for all patients and
236 The
median follow-up time was 34 months (range, 1-297).
237 The
median follow-up time was 35 mo (range, 7-39 mo).
238 Median follow-up time was 35 months (IQR 14-56), with a
239 Median follow-up time was 36 months (IQR 30-46) in the p
240 Median follow-up time was 4 years.
241 The
median follow-up time was 4 years.
242 Median follow-up time was 4.0 years (0.3-8.9).
243 The
median follow-up time was 4.01 years.
244 Median follow-up time was 4.38 years (range, 0.04 to 5.5
245 The
median follow-up time was 4.5 years (range, 6 weeks-25 y
246 Of the 911 recipients, the
median follow-up time was 4.7 years resulting in 4825 pe
247 The
median follow-up time was 4.8 years.
248 Median follow-up time was 4.9 months (range, 0-12 months
249 The median age was 51 and the
median follow-up time was 40 months.
250 The
median follow-up time was 41.9 months.
251 Median follow-up time was 44 months (range, 1 to 226 mon
252 The
median follow-up time was 44 months.
253 The
median follow-up time was 47 months (range, 13 to 80 mon
254 The
median follow-up time was 5 days, the median age was 28
255 Median follow-up time was 5 years (range, 0.4 to 9.4 yea
256 Median follow-up time was 5 years (range, 0.6 to 12.7 ye
257 The
median follow-up time was 5 years with a total of 703 vi
258 The
median follow-up time was 5.0 years (interquartile range
259 Median follow-up time was 5.2 months (range, 1-11).
260 Median follow-up time was 5.4 years (interquartile range
261 The
median follow-up time was 5.6 mo (range, 3.7-23.2 mo).
262 The
median follow-up time was 50 months (range, 2-142 months
263 The
median follow-up time was 52 months (range, 13-118 month
264 The
median follow-up time was 54.3 months (95% CI, 48.4 to 6
265 Median follow-up time was 59 months for patients still a
266 The
median follow-up time was 6.4 years.
267 Median follow-up time was 6.4 years.
268 The
median follow-up time was 6.6 years.
269 Median follow-up time was 6.7 months (IQR 4.4-10.2), wit
270 Median follow-up time was 6.7 years from the time of dia
271 Median follow-up time was 6.7 years per recipient; total
272 Median follow-up time was 60 days for patients with comm
273 The
median follow-up time was 60 months (interquartile range
274 The
median follow-up time was 60 months (range, 1-158 months
275 Median follow-up time was 62.3 months.
276 The
median follow-up time was 7.1 years.
277 Median follow-up time was 7.17 years (range, 0.01 to 11.
278 The
median follow-up time was 7.2 years (range, 0.7-18 years
279 The
median follow-up time was 7.4 years (quartiles, 4.6-10.3
280 Median follow-up time was 7.5 years.
281 The
median follow-up time was 7.6 years (range, 0.1 to 10.1
282 The
median follow-up time was 7.7 mo (range, 0.4-50.1 mo).
283 Median follow-up time was 7.7 years.
284 Median follow-up time was 7.9 years.
285 For the total of patients, the
median follow-up time was 70.3 months.
286 Median follow-up time was 71 months.
287 The
median follow-up time was 72 months (range, 0.2 to 141),
288 Median follow-up time was 74 months.
289 The
median follow-up time was 8.1 years.
290 Median follow-up time was 8.2 years.
291 The
median follow-up time was 8.4 years.
292 The
median follow-up time was 82 months (range, 6-329 months
293 Median follow-up time was 83 months and 58 months for UC
294 The
median follow-up time was 92 months from the completion
295 The
median follow-up time was 922 days.
296 Results
Median follow-up times were 15.0, 21.7, and 14.6 months
297 Mean and
median follow-up times were 2.6 (SD, 1.5) and 2.5 (inter
298 For the rofecoxib and placebo arms,
median follow-up times were 4.84 and 4.85 years, with 24
299 Median follow-up times were 6.1 years and 9.0 years for
300 pants with cardiovascular disease; 4.9 years
median follow-up time)
with fasting lipids, apolipoprote